Cornelis Boersma

Summary

Affiliation: University of Groningen
Country: The Netherlands

Publications

  1. ncbi request reprint Drug costs developments after patent expiry of enalapril, fluoxetine and ranitidine: a study conducted for the Netherlands
    Cornelis Boersma
    Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Groningen University for Drug Exploration GUIDE, Groningen, The Netherlands
    Appl Health Econ Health Policy 4:191-6. 2005
  2. doi request reprint Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands
    Cornelis Boersma
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Clin Ther 32:1103-21. 2010
  3. doi request reprint Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data
    Cornelis Boersma
    Department of Pharmacy, Unit of PharmacoEpidemiology and PharmacoEconomics PE2, University of Groningen, Groningen, The Netherlands
    Am J Cardiovasc Drugs 10:49-54. 2010
  4. pmc Baseline albuminuria predicts the efficacy of blood pressure-lowering drugs in preventing cardiovascular events
    Cornelis Boersma
    Groningen Research Institute of Pharmacy GRIP, University of Groningen, Groningen, The Netherlands
    Br J Clin Pharmacol 65:723-32. 2008
  5. ncbi request reprint An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands
    Cornelis Boersma
    Groningen Research Institute of Pharmacy GRIP, University of Groningen, Groningen, The Netherlands
    Clin Ther 29:963-71. 2007
  6. ncbi request reprint Pharmacoeconomics of angiotensin II antagonists in type 2 diabetic patients with nephropathy: implications for decision making
    Cornelis Boersma
    Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Groningen University Institute for Drug Exploration GUIDE, Groningen, The Netherlands
    Pharmacoeconomics 24:523-35. 2006
  7. ncbi request reprint Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal
    Jarir Atthobari
    Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Groningen UniversityInstitute for Drug Exploration, Groningen, The Netherlands
    Clin Ther 28:432-44. 2006
  8. ncbi request reprint Compliance, persistence, and switching patterns for ACE inhibitors and ARBs
    Stefan Vegter
    Unit of Pharmaco Epidemiology and PharmacoEconomics, Department of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Am J Manag Care 17:609-16. 2011
  9. ncbi request reprint Adherence of pharmacoeconomic studies to national guidelines in the Netherlands
    Jarir Atthobari
    Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Groningen University Institute for Drug Exploration GUIDE, A Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Pharm World Sci 27:364-70. 2005
  10. doi request reprint The association of albuminuria and high-sensitivity C-reactive protein with the efficacy of HMG-coenzyme A reductase inhibitors for cardiovascular event prevention
    Akin Ozyilmaz
    Department of Nephrology, University Medical Center Groningen, University of Groningen, The Netherlands
    Eur J Prev Cardiol 23:847-55. 2016

Detail Information

Publications19

  1. ncbi request reprint Drug costs developments after patent expiry of enalapril, fluoxetine and ranitidine: a study conducted for the Netherlands
    Cornelis Boersma
    Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Groningen University for Drug Exploration GUIDE, Groningen, The Netherlands
    Appl Health Econ Health Policy 4:191-6. 2005
    ..However, drug costs may not decrease after patent expiry, because of a lack of price competition and different national pricing systems...
  2. doi request reprint Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands
    Cornelis Boersma
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Clin Ther 32:1103-21. 2010
    ..Albuminuria is a marker for renal and cardiovascular (CV) risk, allowing early diagnosis of subjects with elevated renal and CV risk...
  3. doi request reprint Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data
    Cornelis Boersma
    Department of Pharmacy, Unit of PharmacoEpidemiology and PharmacoEconomics PE2, University of Groningen, Groningen, The Netherlands
    Am J Cardiovasc Drugs 10:49-54. 2010
    ....
  4. pmc Baseline albuminuria predicts the efficacy of blood pressure-lowering drugs in preventing cardiovascular events
    Cornelis Boersma
    Groningen Research Institute of Pharmacy GRIP, University of Groningen, Groningen, The Netherlands
    Br J Clin Pharmacol 65:723-32. 2008
    ..It could therefore be expected that especially subjects with higher albuminuria levels may benefit from blood pressure-lowering agents to improve their cardiovascular outcome...
  5. ncbi request reprint An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands
    Cornelis Boersma
    Groningen Research Institute of Pharmacy GRIP, University of Groningen, Groningen, The Netherlands
    Clin Ther 29:963-71. 2007
    ..Compared with atenolol, losartan reduced the combined risk for CVD-related morbidity and mortality by 13% (P = 0.021), and reduced the risk for stroke by 25% (P = 0.001), with comparable blood pressure control in both trial arms...
  6. ncbi request reprint Pharmacoeconomics of angiotensin II antagonists in type 2 diabetic patients with nephropathy: implications for decision making
    Cornelis Boersma
    Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Groningen University Institute for Drug Exploration GUIDE, Groningen, The Netherlands
    Pharmacoeconomics 24:523-35. 2006
    ..This will result in a proper pharmacoeconomic outcome, where both types of drugs can be compared for healthcare decisions...
  7. ncbi request reprint Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal
    Jarir Atthobari
    Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Groningen UniversityInstitute for Drug Exploration, Groningen, The Netherlands
    Clin Ther 28:432-44. 2006
    ....
  8. ncbi request reprint Compliance, persistence, and switching patterns for ACE inhibitors and ARBs
    Stefan Vegter
    Unit of Pharmaco Epidemiology and PharmacoEconomics, Department of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Am J Manag Care 17:609-16. 2011
    ..To investigate compliance, persistence, and switching patterns for angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs)...
  9. ncbi request reprint Adherence of pharmacoeconomic studies to national guidelines in the Netherlands
    Jarir Atthobari
    Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Groningen University Institute for Drug Exploration GUIDE, A Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Pharm World Sci 27:364-70. 2005
    ..All Dutch pharmacoeconomic studies that were published in English during 2000-2002 were selected for our review. Two reviewers examined each study for relevance and compared each study with the nine methodological guidelines selected...
  10. doi request reprint The association of albuminuria and high-sensitivity C-reactive protein with the efficacy of HMG-coenzyme A reductase inhibitors for cardiovascular event prevention
    Akin Ozyilmaz
    Department of Nephrology, University Medical Center Groningen, University of Groningen, The Netherlands
    Eur J Prev Cardiol 23:847-55. 2016
    ..Early signs of atherosclerotic vascular damage may identify high-risk patients...
  11. pmc Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature
    Elizabeth J J Berm
    Unit of Pharmacotherapy and Pharmaceutical Care, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    PLoS ONE 11:e0146262. 2016
    ..Due to extended application of pharmacogenetic and pharmacogenomic screening (PGx) tests it is important to assess whether they provide good value for money. This review provides an update of the literature...
  12. ncbi request reprint Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines
    Stefan Vegter
    Groningen Research Institute of Pharmacy GRIP, University of Groningen, Groningen, The Netherlands
    Pharmacoeconomics 26:569-87. 2008
    ..For these goals, we provide a list of recommendations for good pharmacoeconomic practice deemed useful in the fields of pharmacogenetics and pharmacogenomics, regardless of country and origin of the economic analysis...
  13. doi request reprint Economic evaluation of anti-epileptic drug therapies with specific focus on teratogenic outcomes
    Janneke Jentink
    University of Groningen, Groningen, The Netherlands
    J Med Econ 15:862-8. 2012
    ..Anti-epileptic drugs are known to be teratogenic, yet many women do need to continue the anti-epileptic drug use during pregnancy...
  14. doi request reprint On discounting of health gains from human papillomavirus vaccination: effects of different approaches
    Tjalke A Westra
    Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    Value Health 15:562-7. 2012
    ..Different approaches to discount health effects have been proposed. In this study, we estimated the impact of different approaches for discounting health benefits of human papillomavirus (HPV) vaccination...
  15. doi request reprint Quantification of the potential impact of cost-effectiveness thresholds on dutch drug expenditures using retrospective analysis
    Cornelis Boersma
    Unit of PharmacoEpidemiology and PharmacoEconomics PE2, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Value Health 13:853-6. 2010
    ..Yet, since 2005, all new innovative do have to go through a cost-effectiveness evaluation though, with the assessment being focused on the methodology rather than on the exact cost-per-QALY outcome...
  16. doi request reprint Pharmacoeconomic review of recombinant human DNase in the management of cystic fibrosis
    Gerrit S Zijlstra
    Groningen University Institute for Drug Exploration, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands
    Expert Rev Pharmacoecon Outcomes Res 4:49-59. 2004
    ..It is estimated that if dry powder inhalation of deoxyribonuclease I could be used, a reduction in the cost-effectiveness ratio of approximately 40% can be obtained as compared with nebulization...
  17. doi request reprint Economic evaluation of ropinirole prolonged release for treatment of Parkinson's disease in the Netherlands
    Job F M van Boven
    Department of Pharmacy, Unit of PharmacoEpidemiology and PharmacoEconomics PE2, University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands
    Drugs Aging 31:193-201. 2014
    ..In the PREPARED study, ropinirole PR provided a significantly greater improvement in time spent 'off' than ropinirole IR when used as an add-on to levodopa...
  18. doi request reprint Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination
    Mark H Rozenbaum
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Expert Rev Vaccines 10:187-99. 2011
    ..We conclude that the health and economic impact should be addressed in light of the country specific pneumoccocal disease epidemiology to support decisions on immunization programs...
  19. ncbi request reprint Pharmacoeconomics in nephrology: considerations on cost-effectiveness of screening for albuminuria
    Maarten J Postma
    Nephrol Dial Transplant 23:1103-6. 2008